已发表论文

克拉屈滨(Cladribine)治疗严重全身性皮疹的毛细胞白血病:病例报告和文献综述

 

Authors Dong H, Shen Y, Shen Y, Wu D

Received 11 September 2020

Accepted for publication 4 November 2020

Published 19 November 2020 Volume 2020:13 Pages 1187—1192

DOI https://doi.org/10.2147/IJGM.S281476

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Dr Scott Fraser

Abstract: A 49-year-old male patient who had been diagnosed with variable hairy cell leukemia (HCL-V) was treated with interferon for half a year but exert no obvious effect. After two courses of chemotherapy with cladribine, he achieved remission, and splenomegaly significantly improved (the length in craniocaudal dimension decreased from 15.8cm to 11.8cm). Four years later, the patient got disease relapse and was recommended for another cycle of cladribine (6mg for 7 days). On the last day of cladribine, the patient developed fever with needle-like red rashes on the face, limbs, and trunk. At the very beginning, the rash was lighter in color, sparsely distributed, and without obvious itching. Three days later, the rash gradually darkened, expanded and merged, with itching. With the application of high dose gamma globulin and corticosteroids (prednisolone combined with dexamethasone), the rash finally faded, and the patient was discharged. Rash caused by cladribine is not uncommon, such serious and widespread drug-induced rash is rare, and there are few reports. This article reviewed relevant studies and treatments.
Keywords: hairy cell leukemia, cladribine, system rash, side effect